Lantern Pharma Inc.
LTRN
$1.77
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.44% | 11.28% | -10.39% | 30.75% | 4.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -24.59% | -28.67% | -28.72% | -16.02% | -13.99% |
| Operating Income | 24.59% | 28.67% | 28.72% | 16.02% | 13.99% |
| Income Before Tax | -63.29% | 26.62% | 30.65% | 7.29% | 12.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -63.29% | 26.62% | 30.65% | 7.29% | 12.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -63.29% | 26.62% | 30.65% | 7.29% | 12.67% |
| EBIT | 24.59% | 28.67% | 28.72% | 16.02% | 13.99% |
| EBITDA | 24.60% | 28.68% | 28.74% | 16.03% | 14.00% |
| EPS Basic | -41.76% | 29.69% | 33.33% | 7.88% | 12.89% |
| Normalized Basic EPS | -41.75% | 31.06% | 32.69% | 7.87% | 12.88% |
| EPS Diluted | -41.76% | 29.69% | 33.33% | 7.88% | 12.89% |
| Normalized Diluted EPS | -41.75% | 31.06% | 32.69% | 7.87% | 12.88% |
| Average Basic Shares Outstanding | 15.19% | 4.34% | 4.02% | 0.65% | 0.24% |
| Average Diluted Shares Outstanding | 15.19% | 4.34% | 4.02% | 0.65% | 0.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |